M&A / Deals Ambrosia adds a megaround for obesity drugs BioPharma DiveThe $100 million Series B round will be used to bring the biotech s oral GLP-1 into early human testing.M&A / DealsMetabolic & GLP-1Read full story pharminent April 1, 2026 (Last updated: April 1, 2026) BioPharma Dive The $100 million Series B round will be used to bring the biotech s oral GLP-1 into early human testing. M&A / DealsMetabolic & GLP-1Read full story Post navigation Previous: FDA approves new high dose Spinraza regimen for SMANext: FDA Approves First New Molecular Entity Under National Priority Voucher Program Related Stories M&A / Deals BioMarin spends up to $490m for Alesta’s bone disease candidate pharminent August 19, 2026 M&A / Deals J&J hands lymphoma bispecific CAR T back to AbelZeta pharminent August 17, 2026 M&A / Deals Novo Nordisk and AWS form AI partnership to speed drug discovery pharminent August 17, 2026
